Photo of Aria F. Olumi,  MD

Aria F. Olumi, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 643-0237
Fax: (617) 643-4019


aolumi@partners.org

Aria F. Olumi, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Surgery, Harvard Medical School
  • Director, Urology Research Program, Genitourinary Oncology Unit, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

TRAIL, a recently discovered member of the TNF superfamily of cytokines, may be a useful apoptotic-inducing treatment for prostate cancer. However, better understanding the molecular pathways that render a cell TRAIL-sensitive (PC3 and DU145 cells) vs. TRAIL-resistant (LNCaP cells) is crucial in order to selectively offer TRAIL to patients who would maximally benefit from the drug. The focus of my lab is to delineate the molecular mechanisms between TRAIL-resistant and TRAIL-sensitive prostate cancer cells.

Publications

Powered by Harvard Catalyst
  • Bechis SK, Otsetov AG, Ge R, Wang Z, Vangel MG, Wu CL, Tabatabaei S, Olumi AF. Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia. J Urol 2015. PubMed
  • Yun H, Xie J, Olumi AF, Ghosh R, Kumar AP. Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity. 2015. PubMed
  • Ge R, Wang Z, Bechis SK, Otsetov AG, Hua S, Wu S, Wu CL, Tabatabaei S, Olumi AF. DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate. Am J Pathol 2015; 185:870-82. PubMed
  • Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO, Sørensen HT. Metformin use and prostate cancer risk. Eur Urol 2014. PubMed
  • Rodríguez D, Preston MA, Barrisford GW, Olumi AF, Feldman AS. Clinical features of leiomyosarcoma of the urinary bladder: analysis of 183 cases. Urol Oncol 2014. PubMed
  • Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, Loda M, Giovannucci E, Mucci LA, Olumi AF. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med 2014. PubMed
  • Bechis SK, Otsetov AG, Ge R, Olumi AF. Personalized medicine for the management of benign prostatic hyperplasia. J Urol 2014. PubMed
  • Xu R, Horick N, McGovern FJ, Dahl DM, Feldman AS, Blute ML, Olumi AF, Michaelson MD. Prognostic significance of indeterminate lung nodules in renal cell carcinoma. Urol Oncol 2014; 32:355-61. PubMed
  • Aizer AA, Paly JJ, Michaelson MD, Rao SK, Nguyen PL, Kaplan ID, Niemierko A, Olumi AF, Efstathiou JA. Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract 2014; 10:107-12. PubMed
  • Yang H, Chen X, Wang X, Li Y, Chen S, Qian X, Wang R, Chen L, Han W, Ruan A, Du Q, Olumi AF, Zhang X. Inhibition of PP2A activity confers a TRAIL-sensitive phenotype during malignant transformation. Mol Cancer Res 2014; 12:217-27. PubMed
  • Rodríguez D, Barrisford GW, Sanchez A, Preston MA, Kreydin EI, Olumi AF. Primary spermatic cord tumors: disease characteristics, prognostic factors, and treatment outcomes. Urol Oncol 2013; 32:52.e19-25. PubMed
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw 2013; 11:1364-72. PubMed
  • Olumi AF, Kaufman DS, Zietman A, Harisinghani MG, Wu CL. Case records of the Massachusetts General Hospital. Case 25-2013. A 71-year-old man with hematuria and a mass in the bladder. N Engl J Med 2013; 369:660-7. PubMed
  • Fendt SM, Bell EL, Keibler MA, Davidson SM, Wirth GJ, Fiske B, Mayers JR, Schwab M, Bellinger G, Csibi A, Patnaik A, Blouin MJ, Cantley LC, Guarente L, Blenis J, Pollak MN, Olumi AF, Vander Heiden MG, Stephanopoulos G. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res 2013; 73:4429-38. PubMed
  • Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab 2013; 17:372-85. PubMed
  • Olumi AF. Editorial comment. J Urol 2012; 188:2107. PubMed
  • Rodríguez D, Olumi AF. Management of spermatic cord tumors: a rare urologic malignancy. Ther Adv Urol 2012; 4:325-34. PubMed
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol 2012; 30:3071-6. PubMed
  • Lu J, Wirth GJ, Wu S, Chen J, Dahl DM, Olumi AF, Young RH, McDougal WS, Wu CL. A close surgical margin after radical prostatectomy is an independent predictor of recurrence. J Urol 2012; 188:91-7. PubMed
  • Niu Y, Ge R, Hu L, Diaz C, Wang Z, Wu CL, Olumi AF. Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy. Prostate 2011. PubMed
  • Psutka SP, Feldman AS, Rodin D, Olumi AF, Wu CL, McDougal WS. Men with organ-confined prostate cancer and positive surgical margins develop biochemical failure at a similar rate to men with extracapsular extension. Urology 2011. PubMed
  • Olumi AF. Editorial Comment. J Urol 2009. PubMed
  • Zhang X,Huang X,Olumi AF. Repression of NF-kappaB and activation of AP-1 enhance apoptosis in prostate cancer cells. Int J Cancer 2009; 124:1980-9. PubMed
  • Olumi AF,Dewolf WC. The hybrid of basic science and clinical training for the urologic oncologit: Necessity or waste? Urol Oncol 2009; 27:205-7. PubMed
  • Ganapathy M,Ghosh R,Jianping X,Zhang X,Bedolla R,Schoolfield J,Yeh IT,Troyer DA,Olumi AF,Kumar AP. Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. Clin Cancer Res 2009; 15:1601-11. PubMed
  • Pedrosa I,Sun MR,Spencer M,Genega EM,Olumi AF,Dewolf WC,Rofsky NM. MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics 2008; 28:985-1003. PubMed
  • Zhang X, Li W, Olumi AF. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells. Clin Cancer Res 2007; 13:7181-90. PubMed
  • Huang X, Zhang X, Farahvash B, Olumi AF. Novel targeted pro-apoptotic agents for the treatment of prostate cancer. J Urol 2007; 178:1846-54. PubMed
  • Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X, Zhang L, Kim WY, Olumi AF, Kaelin WG. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell 2007; 28:15-27. PubMed
  • Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 2007; 67:9425-34. PubMed
  • Li W, Wu CL, Febbo PG, Olumi AF. Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol 2007; 171:1189-98. PubMed
  • Li L, Zhang L, Zhang X, Yan Q, Minamishima YA, Olumi AF, Mao M, Bartz S, Kaelin WG. HIF LINKED TO DIFFERENTIAL KIDNEY CANCER RISK SEEN WITH TYPE 2A AND TYPE 2B VHL MUTATIONS. Mol Cell Biol 2007; 27:5381-92. PubMed
  • Zhang L, Zhang X, Barrisford GW, Olumi AF. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett 2007; 251:146-57. PubMed
  • Li W, Zhang X, Olumi AF. MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating c-Fos/c-Jun Heterodimers and Repressing c-FLIP(L). Cancer Res 2007; 67:2247-55. PubMed
  • San Francisco IF, Regan MM, Dewolf WC, Olumi AF. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 2006; 175:1341-5; discussion 1345-6. PubMed
Hide